HK inno.N begins selling reflux treatment in Peru

HK inno.N has begun selling its K-CAB tablet, a gastroesophageal reflux disease treatment, in Peru, the pharmaceutical company said Monday.

HK inno.N hosted a symposium in Peru in August ahead of the market release of its Ki-CAB tablet, a gastroesophageal reflux disease treatment, in October. [HK INNO.N]

HK inno.N has begun selling its K-CAB tablet, a gastroesophageal reflux disease treatment, in Peru, the pharmaceutical company said Monday.

The drug was made available in the market starting Oct. 12, under the brand Ki-CAB. The local sales of the drug in Peru as well as 16 other Latin American countries are being handled by Laboratorios Carnot.

Peru is K-CAB’s second destination for market release in the region following Mexico, where HK inno.N began selling the drug in May, and seventh outside Korea.

K-CAB is currently available in China, Mongolia, Philippines, Mexico, Indonesia, Singapore and Peru, through technology or product exports.

HK inno.N has signed technology or product export contracts for K-CAB with a total of 35 countries overseas, such as the United States, China and 18 Latin American nations including Brazil.

BY SHIN HA-NEE [shin.hanee@joongang.co.kr]